

# Sylvain Choquet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6123800/publications.pdf>

Version: 2024-02-01

154  
papers

6,401  
citations

101384

36  
h-index

71532

76  
g-index

160  
all docs

160  
docs citations

160  
times ranked

6434  
citing authors

#	ARTICLE	IF	CITATIONS
1	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	6.3	517
2	Oral Selinexor + Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	13.9	460
3	Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. <i>Blood</i> , 2006, 107, 3053-3057.	0.6	390
4	Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. <i>Lancet Oncology, The</i> , 2012, 13, 196-206.	5.1	349
5	Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Soci�t� Fran�saise de Greffe de Mo�lle Osseuse-Th�rapie Cellulaire. <i>Journal of Clinical Oncology</i> , 2008, 26, 2512-2518.	0.8	301
6	Identification of Prognostic Factors in 61 Patients With Posttransplantation Lymphoproliferative Disorders. <i>Journal of Clinical Oncology</i> , 2001, 19, 772-778.	0.8	211
7	Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas. <i>Clinical Cancer Research</i> , 2012, 18, 5203-5211.	3.2	210
8	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology, the</i> , 2020, 7, e511-e522.	2.2	201
9	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	6.9	189
10	Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 823-833.	0.8	184
11	Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 536-543.	0.8	168
12	Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. <i>Lancet Haematology, the</i> , 2015, 2, e251-e259.	2.2	164
13	Post-transplant lymphoproliferative disorders. <i>Nature Reviews Disease Primers</i> , 2016, 2, 15088.	18.1	161
14	Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenstr�m Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 301-307.	0.8	146
15	CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation. <i>Haematologica</i> , 2007, 92, 273-274.	1.7	143
16	Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. <i>Neuro-Oncology</i> , 2016, 18, 1297-1303.	0.6	135
17	Management and outcome of primary CNS lymphoma in the modern era. <i>Neurology</i> , 2020, 94, e1027-e1039.	1.5	125
18	Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. <i>Annals of Hematology</i> , 2007, 86, 599-607.	0.8	122

#	ARTICLE	IF	CITATIONS
19	Post-Transplantation Lymphoproliferative Disorder After Kidney Transplantation: Report of a Nationwide French Registry and the Development of a New Prognostic Score. <i>Journal of Clinical Oncology</i> , 2013, 31, 1302-1309.	0.8	122
20	Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. <i>Haematologica</i> , 2012, 97, 1751-1756.	1.7	95
21	Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du My��lome. <i>Journal of Clinical Oncology</i> , 2016, 34, 2125-2132.	0.8	91
22	Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma. <i>Neurology</i> , 2015, 84, 325-326.	1.5	84
23	The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. <i>European Journal of Cancer</i> , 2016, 61, 69-76.	1.3	66
24	Characteristic Pattern of Chromosomal Imbalances in Posttransplantation Lymphoproliferative Disorders: Correlation with Histopathological Subcategories and EBV Status. <i>Transplantation</i> , 2005, 80, 176-184.	0.5	65
25	Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series. <i>Neurology</i> , 2017, 88, 101-102.	1.5	65
26	Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. <i>Supportive Care in Cancer</i> , 2017, 25, 3295-3304.	1.0	64
27	Lymphoproliferative disorders after liver transplantation. <i>Journal of Hepatology</i> , 2004, 40, 728-735.	1.8	60
28	Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. <i>Blood</i> , 2011, 117, 1516-1521.	0.6	60
29	Efficacy of lenalidomide in <scp>POEMS</scp> syndrome: A retrospective study of 20 patients. <i>American Journal of Hematology</i> , 2013, 88, 207-212.	2.0	59
30	Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?. <i>Journal of Neuro-Oncology</i> , 2011, 104, 323-330.	1.4	54
31	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020, 34, 2430-2440.	3.3	54
32	Prophylactic intrathecal chemotherapy in primary CNS lymphoma. <i>Journal of Neuro-Oncology</i> , 2012, 106, 143-146.	1.4	51
33	Association of Human Leukocyte Antigen Haplotypes with Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation. <i>Transplantation</i> , 2006, 82, 1093-1100.	0.5	48
34	Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. <i>Journal of Neuro-Oncology</i> , 2017, 133, 315-320.	1.4	47
35	T-cell Therapy Using a Bank of EBV-specific Cytotoxic T Cells. <i>Journal of Immunotherapy</i> , 2014, 37, 170-179.	1.2	42
36	Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a "Proof of Concept" Phase II Study of the French LOC Network. <i>Blood</i> , 2016, 128, 785-785.	0.6	39

#	ARTICLE	IF	CITATIONS
37	Salvage Therapy for Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) With a Second Progression of PTLD After Upfront Chemotherapy: The Role of Single-Agent Rituximab. Transplantation, 2007, 84, 1708-1712.	0.5	34
38	Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network. Blood, 2016, 128, 784-784.	0.6	34
39	CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network. Blood, 2022, 139, 792-796.	0.6	34
40	Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients. British Journal of Haematology, 2017, 176, 37-49.	1.2	32
41	Endogenous Metabolitesâ€Mediated Communication Between OAT1/OAT3 and OATP1B1 May Explain the Association Between <i>SLCO1B1</i> SNPs and Methotrexate Toxicity. Clinical Pharmacology and Therapeutics, 2018, 104, 687-698.	2.3	32
42	Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study. Journal of Clinical Oncology, 2022, 40, 3692-3698.	0.8	31
43	Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients. Haematologica, 2013, 98, e155-e157.	1.7	30
44	Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network. Haematologica, 2015, 100, 1199-1206.	1.7	30
45	Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro-Oncology, 2016, 19, now238.	0.6	30
46	Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire. Blood Advances, 2020, 4, 1357-1366.	2.5	29
47	Efficacy and long-term toxicity of the rituximabâ€fludarabineâ€cyclophosphamide combination therapy in Waldenström's macroglobulinemia. American Journal of Hematology, 2016, 91, 782-786.	2.0	27
48	Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leukemia and Lymphoma, 2008, 49, 2012-2014.	0.6	23
49	Lenalidomide is safe and active in <i>Waldenström</i> macroglobulinemia. American Journal of Hematology, 2015, 90, 1055-1059.	2.0	23
50	Identification of Prognostic Factors in Post-Transplant Lymphoproliferative Disorders. Recent Results in Cancer Research, 2002, 159, 67-80.	1.8	23
51	Clinical and biological features of t(4;14) multiple myeloma: a prospective study. Leukemia and Lymphoma, 2011, 52, 238-246.	0.6	22
52	Sex chromosome loss may represent a disease-associated clonal population in chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2014, 53, 240-247.	1.5	22
53	Endogenous metabolites that are substrates of organic anion transporterâ€™s (OATs) predict methotrexate clearance. Pharmacological Research, 2017, 118, 121-132.	3.1	22
54	Expansion Of Cd4+cd7-T Cells, A Memory Subset With Preferential Interleukin-4 Production, After Bone Marrow Transplantation. Transplantation, 1997, 64, 1453-1459.	0.5	22

#	ARTICLE	IF	CITATIONS
55	Whole Brain Radiotherapy (WBRT) Versus Intensive Chemotherapy with Haematopoietic Stem Cell Rescue (IC + HCR) for Primary Central Nervous System Lymphoma (PCNSL) in Young Patients: An Intergroup Anocéf-Goelams Randomized Phase II Trial (PRECIS). <i>Blood</i> , 2016, 128, 782-782.	0.6	21
56	Granulomatous angitis of the CNS revealing a Hodgkin lymphoma. <i>Neurology</i> , 2013, 80, 323-324.	1.5	19
57	Potiation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis. <i>Joint Bone Spine</i> , 2007, 74, 446-452.	0.8	18
58	Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. <i>Journal of Neuro-Oncology</i> , 2011, 105, 409-414.	1.4	18
59	A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency. <i>European Journal of Haematology</i> , 2018, 101, 48-56.	1.1	18
60	Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control. <i>Ophthalmology</i> , 2016, 123, 2047-2050.	2.5	17
61	Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. <i>Blood</i> , 2020, 135, 1811-1815.	0.6	17
62	Sequential Treatment with the Anti-CD 20 Antibody Rituximab and CHOP+GCSF Chemotherapy in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD): First Interim Analysis of a Multicenter Phase II Study. <i>Blood</i> , 2005, 106, 932-932.	0.6	17
63	Urinary coproporphyrin $\frac{I}{III}$ ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 329-342.	1.1	16
64	The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments. <i>Hematology</i> , 2019, 24, 173-182.	0.7	16
65	Fludarabine in Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 239-242.	0.8	15
66	Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study. <i>Journal of Neuro-Oncology</i> , 2020, 148, 343-352.	1.4	15
67	Chimeric antigen receptor T cells safety: A pharmacovigilance and meta-analysis study. <i>American Journal of Hematology</i> , 2021, 96, 1101-1111.	2.0	14
68	A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study. <i>Neuro-Oncology</i> , 2019, 21, 1039-1048.	0.6	13
69	A Time-Dependent Model Describes Methotrexate Elimination and Supports Dynamic Modification of MRP2/ABCC2 Activity. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 145-156.	1.0	12
70	Identification of PP2A/Set Binding Sites and Design of Interacting Peptides with Potential Clinical Applications. <i>International Journal of Peptide Research and Therapeutics</i> , 2018, 24, 479-488.	0.9	12
71	Cell Penetrating Peptides as a Therapeutic Strategy in Chronic Lymphocytic Leukemia. <i>Protein and Peptide Letters</i> , 2015, 22, 539-546.	0.4	12
72	Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life experience of the French Network. <i>Bone Marrow Transplantation</i> , 2022, 57, 966-974.	1.3	12

#	ARTICLE	IF	CITATIONS
73	Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials. <i>Transplantation</i> , 2018, 102, 1914-1923.	0.5	11
74	Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: Lessons from the randomized European Society for Blood and Marrow Transplantation Intergroup study. <i>American Journal of Hematology</i> , 2014, 89, 174-180.	2.0	10
75	Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia. <i>Cancer Medicine</i> , 2019, 8, 3131-3141.	1.3	10
76	Incidence of Disease Transformation and Development of MDS/AML in 165 Patients with Waldenström's Macroglobulinemia (WM) Treated with Fludarabine (F)-Based Regimen in Three Studies (French) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	0.5	10
77	Optimization of CSF biological investigations for CNS lymphoma diagnosis. <i>American Journal of Hematology</i> , 2019, 94, 1123-1131.	2.0	9
78	Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine, vincristine, and cytarabine for primary CNS lymphoma (PCNSL) in the elderly: An Anocef and Goelams Intergroup study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2032-2032.	0.8	9
79	Risk and Response Adapted Conventional Treatment Strategy in 146 Patients with AL Amyloidosis. <i>Blood</i> , 2014, 124, 2131-2131.	0.6	9
80	Early and Late Posttransplant Lymphoproliferative Disorder After Lung Transplantationâ€”34 Cases From the European PTLD Network. <i>Transplantation</i> , 2013, 96, e18-e19.	0.5	8
81	Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up. <i>Current Opinion in Oncology</i> , 2021, 33, 420-431.	1.1	8
82	Managing immunosuppressive therapy in potentially cured post-kidney transplant cancer (excluding) Tj ETQq0 0 0 rgBT /Overlock 10 T decision-making. <i>Transplant International</i> , 2021, 34, 1789-1800.	0.8	8
83	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021, 21, 993.	1.1	8
84	Impact of plerixafor (mozobil) on hospital efficiency: A single center experience. <i>Journal of Clinical Apheresis</i> , 2018, 33, 5-13.	0.7	7
85	Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination. <i>Seminars in Hematology</i> , 2018, 55, 179-181.	1.8	7
86	Distinct immunopathological mechanisms of EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. <i>American Journal of Transplantation</i> , 2021, 21, 2846-2863.	2.6	7
87	Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gclsg and fcgcl/MW. <i>Blood</i> , 2012, 120, 716-716.	0.6	7
88	Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study. <i>Leukemia and Lymphoma</i> , 2017, 58, 1366-1375.	0.6	6
89	Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S249-S250.	0.2	6
90	Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - A New Standard in Therapy?.. <i>Blood</i> , 2007, 110, 390-390.	0.6	6

#	ARTICLE	IF	CITATIONS
91	Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial.. Blood, 2009, 114, 100-100.	0.6	6
92	Very High Efficiency of ICE (Ifosfamide-Carboplatin-Etoposide) in Relapse/Refractory (R/R) Primary Central Nervous System (PCNSL) and Vitreo-Retinal (VRL) Non Hodgkin Lymphoma. a LOC Network Multicenter Retrospective Study on 58 Cases. Blood, 2015, 126, 1524-1524.	0.6	6
93	Low-Coverage Whole Genome Sequencing of Cell-Free DNA From Immunosuppressed Cancer Patients Enables Tumor Fraction Determination and Reveals Relevant Copy Number Alterations. Frontiers in Cell and Developmental Biology, 2021, 9, 661272.	1.8	6
94	Immunochemotherapy versus rituximab in anti- $\mu$ myelin-associated glycoprotein neuropathy: A report of 64 patients. British Journal of Haematology, 2022, , .	1.2	6
95	CNS involvement at diagnosis in mantle cell lymphoma with atypical MRI features. Journal of Neurology, 2014, 261, 1018-1020.	1.8	5
96	Human Herpesvirus 6 (HHV-6) necrotizing encephalitis, a rare condition in immunocompromised patients: The importance of brain biopsy associated with HHV-6 testing. Journal of the Neurological Sciences, 2017, 377, 112-115.	0.3	5
97	FGFR3 Tyrosine Kinase Inhibitor AB1010 as Treatment of t(4;14) Multiple Myeloma.. Blood, 2007, 110, 413-413.	0.6	5
98	Results of the Largest Study on Post-Transplant-Lymphoproliferations (PTLDs) of the Central Nervous System (CNS) in the Rituximab Era: A Surprising Overrepresentation of Kidney Transplantations, Key Importance of Methotrexate (Mtx), Cytarabine (AraC) and Radiotherapy (RX) for Long Term Survival and Low Impact of Rituximab (R). Blood, 2008, 112, 3614-3614.	0.6	5
99	Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients. Blood, 2015, 126, 816-816.	0.6	5
100	Long Term Efficacy of Rituximab in B-Cell Post Transplantation Lymphoproliferative Disorders (B-PTLD): Update of the Multicenter, Open Label, Phase II Trial (M39037 TRIAL).. Blood, 2006, 108, 2764-2764.	0.6	5
101	Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry. Blood, 2021, 138, 885-885.	0.6	5
102	Clinical features and outcome of patients with primary central nervous system lymphoma admitted to the intensive care unit: a French national expert center experience. Journal of Neurology, 2021, 268, 2141-2150.	1.8	4
103	Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial. Blood, 2014, 124, 3341-3341.	0.6	4
104	Long Term Follow-up of Hematopoietic Stem Cell Transplantation (HSCT) for Primary Plasma Cell Leukemia (pPCL): Final Results of a Prospective Study of IFM Group. Blood, 2016, 128, 4612-4612.	0.6	4
105	Primary Therapy of Waldenström Macroglobulinemia With Nucleoside Analogue-Based Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 227-230.	0.2	3
106	Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 65 Cases in the Modern Era. Blood, 2011, 118, 879-879.	0.6	3
107	Bone involvement in two cases of thoracic primary cutaneous diffuse large B-cell lymphoma, leg type. European Journal of Dermatology, 2011, 21, 744-749.	0.3	3
108	Fludarabine in Waldenström's macroglobulinemia. Expert Review of Hematology, 2013, 6, 229-237.	1.0	2

#	ARTICLE	IF	CITATIONS
109	Neither the patient nor the physician could see anything: Atypical Bingâ€œNeel syndrome. American Journal of Hematology, 2016, 91, 858-859.	2.0	2
110	18F-FDOPA PET/CT Findings in a Patient With Primary Cerebral Amyloidoma. Clinical Nuclear Medicine, 2020, 45, e206-e207.	0.7	2
111	Abstract CT132: A Phase 2b randomized study of selinexor in patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) demonstrates durable responses in both GCB & Non-GCB subtypes. , 2017, , .		2
112	Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study. Blood, 2018, 132, 1677-1677.	0.6	2
113	Serum Free Light Chain (SFLC) Elevation Is Associated with High $\hat{I}^{22}$ -Microglobulin and with a Shorter Time to Treatment in Waldenströ™m Macroglobulinemia (WM).. Blood, 2006, 108, 2419-2419.	0.6	2
114	Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW. Blood, 2011, 118, 2854-2854.	0.6	2
115	High Efficiency of ICE (Ifosfamide-Carboplatin-Etoposide) in Relapse/Refractory Primary Central-Nervous System and Intra-Ocular Non Hodgkin Lymphoma, After First Line Treatment Containing High Doses of Methotrexate and Cytarabine. A Monocentric Retrospective Study From 2010 to 2012 On 17 Cases. Blood, 2012, 120, 3664-3664.	0.6	2
116	The Spectrum Of Cold Agglutinin Disease At The Era Of Rituximab: A Retrospective Study On 48 Patients. Blood, 2013, 122, 2193-2193.	0.6	2
117	The French LOC Network for Primary CNS Lymphoma (PCNSL) Patients: What Can We Learn from a Large National Database?. Blood, 2016, 128, 926-926.	0.6	2
118	IL10 and IL10:IL6 Ratio in CSF Is Useful at Diagnosis but Also in the Assessment of Therapeutic Response in Patients with Primary Central Nervous System Lymphoma (PCNSL). Blood, 2014, 124, 1619-1619.	0.6	2
119	Hidden in the Eyesâ€œRecurrence of Systemic Hemopathies Reportedly â€œIn Remissionâ€œ Six Cases and Review of Literature. Medicina (Lithuania), 2022, 58, 456.	0.8	2
120	Primary CNS lymphoma of the corpus callosum: presentation and neurocognitive outcomes. Journal of Neuro-Oncology, 2022, , 1.	1.4	2
121	Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study. Hematological Oncology, 2022, 40, 976-986.	0.8	2
122	Current and future therapeutic approach for Waldenströ™mâ€™s macroglobulinemia. Immunotherapy, 2014, 6, 333-348.	1.0	1
123	Neurolymphomatosis as a relapse of primary cerebral nervous system lymphoma. Leukemia and Lymphoma, 2017, 58, 729-731.	0.6	1
124	A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S248-S249.	0.2	1
125	A Prospective Phase II Trial of Lenalidomide and Dexamethasone in POEMS Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e41.	0.2	1
126	Successful treatment of an EBVâ€œpositive HIVâ€œassociated polymorphic Bâ€œcell lymphoproliferative disorder by rituximab monotherapy. EJHaem, 2021, 2, 562-564.	0.4	1



#	ARTICLE	IF	CITATIONS
127	Successful treatment with adapted high dose methotrexate in a hemodialysis patient with primary central nervous system lymphoma: 100 mg/m <sup>2</sup> seems sufficient. <i>Nefrologia</i> , 2022, 42, 130-134.	0.2	1
128	Use of Human Immunoglobulins in Secondary Immunodeficiencies Associated with Hematological Malignancy in Real-Life Practice: Which Patients, Which Treatment?. <i>Blood</i> , 2014, 124, 4972-4972.	0.6	1
129	Central Nervous System Involvement in Chronic Lymphocytic Leukemia: Diagnosis and Treatment in a Retrospective Cohort of Thirty Patients. <i>Blood</i> , 2015, 126, 2948-2948.	0.6	1
130	To Dose or Not to Dose: Are IL-10 and IL-6 Accurate Biomarkers to Detect Leptomeningeal Involvement in Small B-Cell Lymphoproliferation?. <i>Blood</i> , 2015, 126, 3878-3878.	0.6	1
131	The Gain of the Short Arm of Chromosome 2 (2p+) Induces XPO1 Overexpression and Drug Resistance in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 492-492.	0.6	1
132	Management of Post-Transplant Lymphoproliferative Disorders in the Real Life: The French Attitude Between 2010 and 2013. <i>Blood</i> , 2016, 128, 4230-4230.	0.6	1
133	Lenalidomide in the treatment of relapsed primary central nervous system lymphoma (PCNSL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 2079-2079.	0.8	1
134	Familial Chronic lymphoid leukemia (CLL): state of the art. <i>Hematologie</i> , 2012, 18, 182-188.	0.0	1
135	In situ off-line extracorporeal photopheresis conducted in a real-life situation at a Hemobiotherapy Department in France: A comparison of costs vs on-line procedure. <i>Journal of Clinical Apheresis</i> , 2021, , .	0.7	1
136	Radical Improvement in Prognosis of CNS Ptlds Using Methotrexate Dose Alorithm Regardless of Renal Function. <i>Blood</i> , 2021, 138, 2521-2521.	0.6	1
137	Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients. <i>Blood</i> , 2021, 138, 452-452.	0.6	1
138	Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	1
139	Glomeruloid haemangioma: a possible consequence of elevated VEGF in POEMS and Erdheim-Chester disease. <i>European Journal of Dermatology</i> , 2018, 28, 784-789.	0.3	1
140	Immunotherapy in Waldenström's Macroglobulinemia. , 2017, , 315-326.		0
141	A clinical trial combining megakaryocytes and haematopoietic stem cells to promote engraftment after autologous transplantation. <i>British Journal of Haematology</i> , 2018, 183, 139-142.	1.2	0
142	Post-Heart Transplantation Lymphoproliferations. , 2018, , .		0
143	Automated differential white blood cell count and cytological analysis can detect near-tetraploid cells in chronic lymphoproliferative disorders. <i>International Journal of Laboratory Hematology</i> , 2019, 41, e104-e108.	0.7	0
144	MIROIR: 4-Year Interim Analysis of a Multicenter, Non-Interventional Study in France of Pomalidomide in Relapsed or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e253-e254.	0.2	0

#	ARTICLE	IF	CITATIONS
145	Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1563-1567.	0.6	0
146	Prevention of Post Transplantation Lymphoproliferative Disorders by Adapted Management of EBV Reactivations. A Monocentric Prospective Study on 101 Patients.. <i>Blood</i> , 2006, 108, 2932-2932.	0.6	0
147	A Prospective Study of t(4;14) Multiple Myeloma.. <i>Blood</i> , 2007, 110, 414-414.	0.6	0
148	Combination of Bortezomib and Dexamethasone (VD) or Bortezomib, Adriamycine and Dexamethasone (PAD) Followed by High Dose Therapy and Peripheral Blood Stem Cell Transplantation in First-Line Treatment of T(4;14) Multiple Myeloma : a Prospective Study of the MAG Group.. <i>Blood</i> , 2009, 114, 3408-3408.	0.6	0
149	Anti-MAG Neuropathy: a Single Center Retrospective Study In 61 Patients. <i>Blood</i> , 2010, 116, 3951-3951.	0.6	0
150	Adapted Management of EBV Reactivation After Solid Organ Transplantation: An Effective Prevention of Post Transplantation Lymphoproliferative Disorders (PTLD). Results of the Largest Prospective Study on 251 Patients. <i>Blood</i> , 2010, 116, 592-592.	0.6	0
151	Pulmonary Infiltration in Anaplastic T-Cell Lymphoma. , 2011, , 787-791.		0
152	Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLD-1 Trial. <i>Blood</i> , 2011, 118, 878-878.	0.6	0
153	High Efficiency and Tolerance of Temozolomide in Relapse/Refractory Primary Intra-Ocular Lymphoma (R/R PIOL). a Retrospective Multicentric Study from the LOC Network. <i>Blood</i> , 2014, 124, 3080-3080.	0.6	0
154	Successful treatment with adapted high dose methotrexate in a hemodialysis patient with primary central nervous system lymphoma: 100 mg/m2 seems sufficient. <i>Nefrologia</i> , 2022, 42, 130-134.	0.2	0